Last reviewed · How we verify

Lennox-Gastaut syndrome — Treatment Landscape & Competitive Intelligence

Lennox-Gastaut syndrome (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Lennox-Gastaut syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Epidiolex CANNABIDIOL Jazz Pharms Res Caspase-1 2018-01-01
Onfi CLOBAZAM Lundbeck Pharms Llc Benzodiazepine [EPC] GABA-A receptor alpha-1/beta-2/gamma-2 2011-01-01
Banzel RUFINAMIDE Eisai rufinamide Carbonic anhydrase 5A, mitochondrial 2008-01-01
Felbatol FELBAMATE Mylan Speciality Lp Anti-epileptic Agent [EPC] NMDA receptor-ionophore complex 1993-01-01
Ativan lorazepam Generic (originally Wyeth/Pfizer) Benzodiazepine [EPC] GABA-A receptor alpha-1/beta-3/gamma-2, Fatty acid-binding protein, liver 1977-09-30
Klonopin clonazepam Generic (originally Roche) Benzodiazepine [EPC] GABA-A receptor alpha-1/beta-2/gamma-2, GABA-A receptor; anion channel, GABA-A receptor; anion channel 1975-06-04
Tegretol carbamazepine Novartis AG (originally Geigy) Mood Stabilizer [EPC] Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4 1968-03-11
Mysoline PRIMIDONE Bausch Health Anti-epileptic Agent [EPC] Transient receptor potential cation channel subfamily M member 3 1954-01-01
Phenytoin Sodium PHENYTOIN Viatris Anti-epileptic Agent Sodium channel protein type 2 subunit alpha 1953-01-01
Dilantin Phenytoin Sodium Pfizer phenytoin Nuclear receptor subfamily 1 group I member 3 1953-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Ataturk University · 1 drug in Lennox-Gastaut syndrome
  2. Bausch Health · 1 drug in Lennox-Gastaut syndrome
  3. Eisai · 1 drug in Lennox-Gastaut syndrome
  4. Enanta Pharmaceuticals, Inc · 1 drug in Lennox-Gastaut syndrome
  5. GSK · 1 drug in Lennox-Gastaut syndrome
  6. Generic (originally Roche) · 1 drug in Lennox-Gastaut syndrome
  7. Generic (originally Wyeth/Pfizer) · 1 drug in Lennox-Gastaut syndrome
  8. Institute of Child Health · 1 drug in Lennox-Gastaut syndrome
  9. Janssen · 1 drug in Lennox-Gastaut syndrome
  10. Jazz Pharms Res · 1 drug in Lennox-Gastaut syndrome
  11. Lundbeck Pharms Llc · 1 drug in Lennox-Gastaut syndrome
  12. Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · 1 drug in Lennox-Gastaut syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Lennox-Gastaut syndrome:

Cite this brief

Drug Landscape (2026). Lennox-Gastaut syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/lennox-gastaut-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing